ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Show more

Location: 2000 Frontis Plaza Blvd., Winston-Salem, NC, 27103, United States | Website: https://prokidney.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.812B

52 Wk Range

$0.46 - $7.13

Previous Close

$5.18

Open

$4.81

Volume

17,749,272

Day Range

$4.48 - $5.45

Enterprise Value

1.12B

Cash

328.5M

Avg Qtr Burn

-30.32M

Insider Ownership

30.05%

Institutional Own.

41.66%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.